Long Term Vitamin D Therapy in HCV Treated Patients (VD-HCV)

Dr. Nadia AbdelAaty AbdelKader

Status and phase

Terminated

Phase 3

Conditions

Chronic Hepatitis C

Treatments

Drug: Vitamin D

Study type

Interventional

Funder types

Other

Identifiers

NCT01997203

HCV-VD2013

Details and patient eligibility

About

Treatment of hepatitis C virus (HCV) infection was carried out using pegylated interferon (PEG-IFN), ribavirin (RBV) and vitamin D (vit D) for 48 weeks in HCV genotypes 4a subjects. The purpose of this study is to determine the effect of vitamin D on liver affection in such patients.

Full description

Fifty patients study group administered vit D were compared with 50 patients control group without vit D. The results showed a significant elevation in vit D levels during the time period, and significant reduction on HCV RNA from the 12th wk to reach zero level in 24th wk. Interleukin 6 (IL-6), visfatin and hyaluronic acid levels were reduced significantly to reach normal values. These concentrations reduction by the effect of vit D on HCV indicated the reduction in inflammation, infection and liver cirrhosis and nearly amelioration HCV.

Enrollment

100 patients

Sex

All

Ages

18 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Chronic HCV infection (positive HCV Ab more than 6 months)
Treated with pegylated interferon and ribavirin

Exclusion criteria

Coinfection with Hepatitis B or Hepatitis D or Human Immunodeficiency Virus
Previous non response to antiviral therapy.
Other causes of chronic liver diseases as schistosomiasis, Wilson disease and alcoholic liver disease.